Rhythm Pharmaceuticals, Inc (RYTM)

Etorro trading 970x250
Rhythm Pharmaceuticals, Inc (RYTM) Logo

About Rhythm Pharmaceuticals, Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company’s lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Address: 222 Berkeley Street, Boston, MA, United States, 02116

Rhythm Pharmaceuticals, Inc News and around…

Latest news about Rhythm Pharmaceuticals, Inc (RYTM) common stock and company :

Sum Up The Pieces: XBI Could Be Worth $212
22 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $212.34 per unit.

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
19 Nov, 2021 FinancialContent

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:EQT) from Equal-Weight to Overweight. For the ...

Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome
15 Nov, 2021 Yahoo! Finance

FDA sets PDUFA goal date of March 16, 2022BOSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bar

Rhythm Pharmaceuticals to Present at Stifel 2021 Virtual Healthcare Conference
09 Nov, 2021 Yahoo! Finance

BOSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 11:20 a.m. ET. A live webcast of the presentation will be available under “Events & Presentations”

Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results
02 Nov, 2021 Yahoo! Finance

-- U.S. and EU regulatory filings submitted for IMCIVREE® (setmelanotide) for treatment of Bardet-Biedl and Alström syndromes; launch preparations underway ---- Delivered a total of 22 presentations at three major medical conferences -- -- New presentations include first-ever data showing improvements in health-related quality of life in rare genetic diseases of obesity ---- IMCIVREE third quarter net sales reach $1M ---- Management to Host Conference Call at 8:00 a.m. ET -- BOSTON, Nov. 02, 202

Earnings Scheduled For November 2, 2021
02 Nov, 2021 FinancialContent

Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per ...

Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021
01 Nov, 2021 Yahoo! Finance

-- Additional oral presentation details safety and efficacy data from Phase 3 trial of setmelanotide in BBS ---- Also presenting new hunger data from SRC1 and SH2B1 cohorts in Phase 2 Basket Trial and new data on utilization of URO® genetic testing program – BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, this week presente

Analysts Anticipate VHT Will Reach $289
22 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $289.40 per unit.

Rhythm Pharmaceuticals to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
20 Oct, 2021 Yahoo! Finance

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 2, 2021 to report its third quarter 2021 financial results and provide a corporate update. To access the live conference call, please dial (844) 498-0570 (domestic) or (40

Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström Syndromes
14 Oct, 2021 Yahoo! Finance

BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it has submitted its Type II variation application to the European Medicines Agency (EMA) for IMCIVREE® (setmelanotide) for the treatment of obesity and control of hunger in adult and pediatric patients six years of age and older with Bardet-Biedl syndrome

Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity® Genetic Testing Program
14 Oct, 2021 Yahoo! Finance

-- New data in patients with POMC or LEPR deficiency obesity show setmelanotide led to clinically meaningful improvements in health related quality of life measures and hunger -- -- Updated results from Uncovering Rare Obesity® testing program suggest up to 64.5 percent of individuals with early-onset, severe obesity may carry variants linked to rare genetic diseases of obesity -- -- Additional posters include encore presentations of data from Phase 3 trial evaluating setmelanotide in BBS and Ph

Scientist behind Vertex CF drugs launches new startup with Atlas Venture
14 Oct, 2021 Yahoo! Finance

Jonathan Moore, one of the first employees of Vertex Pharmaceuticals Inc. and a key scientist behind the company's renowned cystic fibrosis drugs, has a new venture called Rectify Pharmaceuticals.

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Here's Why We're Not Too Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Situation
11 Oct, 2021 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Rhythm Pharma's Imcivree Wins UK Approval For Obesity, Hunger Control
22 Sep, 2021 FinancialContent

Britain'sMedicines & Healthcare Products Regulatory Agency (MHRA) has approvedRhythm Pharmaceuticals ...

Rhythm Pharmaceuticals Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE Meeting
22 Sep, 2021 FinancialContent
CORRECTION: Rhythm Pharmaceuticals, Inc.
21 Sep, 2021 Yahoo! Finance

BOSTON, Sept. 21, 2021 (GLOBE NEWSWIRE) -- In a release issued on Wednesday, September 21 by Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), please note that the symbol ▼ was erroneously omitted from the headline. The corrected release follows: Rhythm Pharmaceuticals Announces Marketing Authorisation of ▼IMCIVREE® (setmelanotide) in Great Britain – IMCIVREE is indicated for treatment of obesity and control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocort

Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain
21 Sep, 2021 FinancialContent
Analysts Anticipate IWV Will Reach $291
21 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 3000 ETF (IWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $290.81 per unit.

Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (setmelanotide) for the treatment of obesity and control of hunger i
20 Sep, 2021 FinancialContent
Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (setmelanotide) for the treatment of obesity and control of hunger in Bardet-Biedl and Alström Syndromes
20 Sep, 2021 Yahoo! Finance

BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it has completed its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for IMCIVREE® (setmelanotide) for the treatment of obesity and control of hunger in adult and pediatric patients 6 years of age and older with Bardet

The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
09 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Rhythm Pharmaceuticals Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome
08 Sep, 2021 FinancialContent

Expanded access program may allow access for eligible patients in the United States who have no authorized treatment options

Rhythm Pharmaceuticals Announces CMO Transition
02 Sep, 2021 FinancialContent
Rhythm Pharmaceuticals to Present at Morgan Stanley 19th Annual Global Healthcare Conference
02 Sep, 2021 FinancialContent
Commit To Buy Rhythm Pharmaceuticals At $7.50, Earn 14.2% Annualized Using Options
20 Aug, 2021 FinancialContent

Investors considering a purchase of Rhythm Pharmaceuticals Inc (RYTM) shares, but tentative about paying the going market price of $11.80/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2022 put at the $7.50 strike, which has a bid at the time of this writing of 45 cents..

Stocks That Hit 52-Week Lows On Friday
20 Aug, 2021 FinancialContent

On Friday morning, 155 companies achieved new lows for the year. Interesting Points: Marqeta (NASDAQ:MQ) ...

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Thursday
19 Aug, 2021 FinancialContent

Thursday morning, 173 companies reached new 52-week lows. Areas of Interest: The largest company by market ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Rhythm Pharmaceuticals, Inc (RYTM) is a NASDAQ Common Stock listed in , ,

970x250